Newsroom

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025

November 17, 2025

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Epigenetic editors are a gentler form of gene editing

February 24, 2025

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Media Center

Media

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Read Now

Press Release

Epigenetic editors are a gentler form of gene editing

February 24, 2025

The Economist

Read Now

Media

CRISPR’s cardio catch-all drives a biotech’s broad potential

February 18, 2025

PharmaVoice

Read Now

Press Release

CRISPR’s cardio catch-all drives a biotech’s broad potential

February 18, 2025

PharmaVoice

Read Now

Media

Towards an AI-Driven CRISPR Future

February 11, 2025

SynBioBeta

Read Now

Press Release

Towards an AI-Driven CRISPR Future

February 11, 2025

SynBioBeta

Read Now

Media

2025 predictions: Which trends are set to shape the biotech industry this year?

January 13, 2025

Labiotech

Read Now

Press Release

2025 predictions: Which trends are set to shape the biotech industry this year?

January 13, 2025

Labiotech

Read Now

Press Release

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now

Press Release

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now

Press Release

Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

Read Now

Press Release

Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

Read Now

Media

BioSpace 40 Under 40

October 7, 2025

BioSpace

Read Now

Media

Treating High Cholesterol Could Become A One-And-Done Treatment

September 23, 2025

Forbes

Read Now

Media

Getting to the Heart of CRISPR-Based Therapies

July 22, 2025

The Scientist

Read Now

Media

Advancing CRISPR Cures Requires Cross-Sector Collaboration

June 13, 2025

Genetic Engineering & Biotechnology News

Read Now

Media

U.S. Innovation, Strategy Needed to Counter China’s Rise in Biotech

May 29, 2025

The Wall Street Journal

Read Now

Media

Heart Disease Could Be a Goner When These New Drugs Arrive

May 23, 2025

Barron's

Read Now

Press release

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

September 2, 2026

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Investor Conferences

September 1, 2026

Read Now

Press release

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

July 27, 2026

Read Now

Press release

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

July 23, 2026

Read Now

Press release

Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials

June 18, 2026

Read Now

Press release

Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose

May 28, 2026

Read Now

Blog

Publications

Publication

Sequential Proofreading Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

August 31, 2026

bioRxiv

Read Now

Publication

Engineered Allosteric Control Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors

January 14, 2026

bioRxiv

Read Now

Publication

Single particle charge detection mass spectrometry enables molecular characterization of lipid nanoparticles and mRNA packaging

May 18, 2025

Journal of Controlled Release

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now